Kura Oncology prices $100M public offering of common stock and pre-funded warrants

Kura Oncology, Inc.

Offering of 5,660,871 common shares at $11.50 and 3,034,782 pre-funded warrants at $11.4999 per warrant.
Expected net proceeds of $93.6M; closing on June 16, 2023.
Underwriters granted 30-day option to buy up to 1,304,347 additional shares.
BofA Securities, Jefferies and SVB Securities are joint bookrunning managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.